Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...

Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for the novel, potential ...

Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European ...

At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ...

Some patients with non-small cell lung cancer saw a 49% reduction in the risk of disease progression or death with ...

If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Data from a Phase 3 study has revealed that ivonescimab demonstrates a statistically significant and clinically meaningful ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...